Core Viewpoint - The Chinese pharmaceutical industry is experiencing a significant transformation, moving from a focus on generic drugs to global innovation, driven by an increase in business development (BD) activities and the emergence of the NewCo model [1][2][5]. Group 1: Market Performance - The Hang Seng Index opened up by 0.74% and the Hang Seng Tech Index by 0.97% on June 5, 2025, indicating positive market sentiment [1]. - The Hang Seng Healthcare ETF (513060) saw a more than 1% increase in intraday trading, with a trading volume exceeding 500 million yuan and a turnover rate of over 6% [1]. - Year-to-date, the Hang Seng Healthcare ETF has risen nearly 40%, reflecting strong market interest [1]. Group 2: Business Development Trends - Since 2024, there has been a notable increase in the volume and value of outbound BD transactions for Chinese innovative drugs, with significant deals in areas such as ADCs, bispecific antibodies, and GLP-1 assets [2]. - The total value of License-out transactions in the innovative drug sector has surged from approximately $11 billion in 2020 to over $51 billion in the first ten months of 2024, showcasing a substantial growth trend [2]. - The increase in transaction size and number is attributed to upgraded transaction structures, enhanced international recognition, and innovative business models like the NewCo model [2]. Group 3: NewCo Model Advantages - The NewCo model addresses challenges such as financing difficulties, monetization issues, and high R&D risks by creating independent companies through partnerships between domestic biotech firms and foreign investors [3][4]. - This model allows for increased financing and monetization channels, enabling independent fundraising while retaining traditional License-out revenue [3]. - It also reduces R&D and commercialization risks by outsourcing high-cost clinical development and market promotion to the NewCo or partners [4]. Group 4: Future Outlook - The pharmaceutical sector is poised for positive development, having completed a transition from old to new growth drivers, with a focus on innovation over generics [5]. - Companies like Heng Rui, Han Sen, and Ke Lun have successfully transformed into innovative players, while outbound capabilities continue to improve [5]. - The rise of AI in healthcare is expected to unlock new growth opportunities, with a recommendation to focus on innovative drugs, outbound strategies, and high-barrier industries [5].

Core Viewpoint - WuXi Biologics (02269.HK) shows a recovering stock price trend, indicating market optimism for its future performance [1][11]. Price Performance - The stock price closed at HKD 24.95 on June 2, 2025, with a stable trading day and a cumulative volatility of 10.8% over the past week, suggesting potential for a breakthrough [1]. - In just two days, the stock price increased by 6.62%, positively impacting related derivative products, with notable performances from JPMorgan and UBS leveraged products, which rose by 28% and 20% respectively [1][7]. Technical Analysis - Support levels for WuXi Biologics are identified at HKD 22.9 and HKD 23.5, confirming bottom support as the stock stabilizes above these levels [3]. - Resistance levels are at HKD 25.8 and HKD 26.8; a breakthrough of the first resistance could lead to a new upward trend [3]. - The probability of an upward movement is assessed at 53%, indicating a neutral to bullish sentiment [3]. Technical Signals - A strong buy signal is indicated by 17 technical signals supporting a bullish outlook, including moving averages and mid-term trend indicators [6]. - The MACD and Ichimoku indicators also provide buy signals, reinforcing expectations for trend continuation [6]. Derivative Products - For bullish investors, the Bank of China call option (15841) offers a stable choice with a leverage of 3.3 times and an exercise price of HKD 24.88, minimizing time decay impact [7]. - For higher leverage, the Morley call option (14687) provides a leverage of 1.9 times, suitable for short-term trading [7]. - Investors interested in bull certificates may consider JPMorgan's product (57118), which offers a leverage of 5.3 times with a recovery price of HKD 22 [7]. Market Outlook - The overall market sentiment is positive, with expectations for further upward movement if the stock can effectively break through the key resistance level of HKD 25.8 [11]. - The stock is currently in a stabilizing phase, and any short-term fluctuations should be viewed as a healthy consolidation process for future gains [11].

Core Insights - The 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago showcased a record 73 oral reports on innovative drugs from China, highlighting the rapid development of domestic innovative pharmaceuticals [1] - The Hong Kong Stock Connect medical ETF (513200) has seen a year-to-date increase of 42.23%, while the Hang Seng Innovative Drug ETF (159316) has surged by 52.19%, indicating strong market performance in the innovative drug sector [1] - The Chinese innovative drug industry is entering a new phase of profitability, with leading biotech companies beginning to expand internationally, suggesting a favorable investment outlook [2] Investment Landscape - The innovative drug sector is identified as a core investment theme within the pharmaceutical and biotechnology industry, characterized by high certainty and leadership potential [2] - E Fund's medical industry index products cover A-shares, Hong Kong stocks, and U.S. stocks, with a total scale of nearly 27 billion yuan across six medical-related ETFs, making it a leader in the industry [3] - The Hang Seng Innovative Drug ETF (159316) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which includes leading companies in the innovative drug field, with significant exposure to biotechnology and chemical pharmaceuticals [4] Key Holdings - The top holdings in the Hang Seng Innovative Drug Index include Innovent Biologics, CanSino Biologics, and WuXi Biologics, each with a weight exceeding 8% [5] - The index's price-to-earnings ratio stands at 22.96, indicating a higher safety margin compared to historical averages [6] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 liquid and large-cap healthcare companies, reflecting the overall performance of the sector [6][8]

Market Performance - As of June 4, 2025, the Shanghai Composite Index rose by 0.42% to 3376.20 points, while the Shenzhen Component Index increased by 0.87% to 10144.58 points, and the ChiNext Index climbed by 1.11% to 2024.93 points [1] - The total trading volume of both markets reached 1.15 trillion yuan, marking the fifth consecutive day of exceeding one trillion yuan [1] - The jewelry sector showed strong performance with a daily increase of 5.95%, followed by leisure food and personal care products, which rose by 4.45% and 3.37% respectively [1] ETF Performance - A total of 1049 non-currency ETFs in the market increased, with an increase ratio of 91% [1] - The Hang Seng Innovative Drug Index rose by 3.83%, with related ETFs also showing significant gains of 3.61% and 3.55% [1] - The latest share size of the Hang Seng Innovative Drug ETF (520500.SH) reached 366 million shares, closely tracking the performance of the Hang Seng Innovative Drug Index [3] Valuation Metrics - The latest P/E ratio (PE-TTM) for the Hang Seng Innovative Drug Index is 26.92, which is lower than the average of over 11.03% in the past three years [4] - The P/E ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index stands at 26.64, also below the average of over 12.16% in the last three years [5] - The National Certificate Hong Kong Stock Connect Innovative Drug Index has a P/E ratio of 29.36, lower than the average of over 10.84% in the past three years [5] Declining ETFs - A total of 71 non-currency ETFs declined, with a decrease ratio of 6% [5] - The top declining ETFs included the Greater Bay Area ETF, which fell by 1.41%, and the Transportation ETF, which decreased by 0.82% [7] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 24.67%, while the S&P 500 Index had a premium of 17.11% [8] - The top ETFs by premium rate included the S&P Consumer ETF (24.67%) and the S&P 500 ETF (17.11%) [10]

五大不同点 1、成分股选取 中证港股通医疗主题指数：从港股通证券范围内选取50只业务涉及医疗器械、医疗商业与服务、制药与生物科技服务等领域的上市公司证券作为指数样本。 不过目前成分股数量为47只，个股平均市值约439亿元。 每经记者｜黄小聪 每经编辑｜赵云 今日，港股创新药板块继续上涨，此前我们对比了恒生创新药和港股创新药的不同。 这一期，我们继续围绕医药板块，来关注恒生医疗和港股医疗主题。这两个主题的ETF，主要跟踪的是中证港股通医疗主题指数、恒生医疗保健指数和恒生 港股通医疗保健指数。 它们都有哪些异同点呢？ | 最大値 | 2,399.79 | | --- | --- | | 平均值 | 438.87 | | 中位数 | 259.61 | | 最小值 | 29.35 | | 류计 | 20.626.95 | 恒生医疗保健指数：包括恒生综合指数中所有归类为医疗保健业的成分股，成分股数量较多，目前共有68只。个股平均市值约343亿元。 | 元) | | | --- | --- | | 最大値 | 2,328.9 | | 平均值 | 343.1 | | 中位数 | 145.6 | | 最小値 | 16.0 | ...

Core Viewpoint - The recent surge in the Hong Kong stock market, particularly in the innovative drug sector, is attributed to significant inflows of capital and positive developments in clinical research, indicating a robust growth trajectory for the industry [1][3][4]. Group 1: Market Performance - The Hong Kong stock market showed slight gains, with the Hong Kong Stock Connect innovative drug ETF (159570) rising by 3.88% and achieving a trading volume exceeding 5 billion yuan [1]. - The ETF experienced a net inflow of over 21 million yuan during the trading session, following a substantial inflow of over 91 million yuan the previous day [1]. Group 2: Company Developments - The constituent stocks of the Hong Kong Stock Connect innovative drug ETF saw collective gains, with notable increases such as over 15% for Innovent Biologics and over 3% for both CSPC Pharmaceutical Group and CanSino Biologics [3]. - Innovent Biologics presented promising clinical data at the 2025 ASCO annual meeting, showcasing its first-in-class PD-1/IL-2α-bias bispecific antibody IBI363 for treating advanced non-small cell lung cancer [3]. - Morgan Stanley has raised its sales forecasts for Innovent's products, indicating strong potential for IBI363 and IBI343 in both domestic and international markets [3]. Group 3: Industry Trends - The current wave of innovation in the pharmaceutical sector is seen as a natural progression of China's pharmaceutical industry, with a significant increase in the number of innovative drugs entering the market [4]. - The period from 2025 to 2028 is projected to be critical for Chinese innovative drug companies as they are expected to collectively enter a profitability phase, marking a significant shift in the industry [4]. - The ASCO conference highlighted a record number of 73 oral presentations for Chinese innovative drug assets, reflecting the growing international recognition and demand for these products [5]. Group 4: Investment Opportunities - The Hong Kong Stock Connect innovative drug ETF (159570) is noted for its high concentration in innovative drug companies, with over 72% of its top ten holdings in leading firms [9]. - The ETF is characterized by a high weight of innovative drugs (up to 85%) and a relatively low valuation compared to the market, making it an attractive investment option [9]. - The Chinese innovative drug sector is experiencing a surge in business development (BD) activities, with increasing recognition and transaction values for innovative drug assets [6][7].

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly focusing on the performance of companies like Innovent Biologics and Hansoh Pharmaceutical, driven by clinical trial results and strategic partnerships [1][2]. - Innovent Biologics reported promising Phase I clinical trial data for its first-in-class PD-1/IL-2α-bias bispecific antibody IBI363, showing controllable safety and encouraging efficacy in treating advanced non-small cell lung cancer [1]. - Morgan Stanley raised the target price for Innovent Biologics from HKD 55 to HKD 74, reflecting increased confidence in its pipeline, particularly IBI363 and IBI343, maintaining an "overweight" rating [1]. Group 2 - Hansoh Pharmaceutical entered a licensing agreement with Regeneron, granting global exclusive rights (excluding mainland China, Hong Kong, and Macau) for the development and commercialization of HS-20094, with an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion [2]. - The pharmaceutical industry is expected to experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of new medical insurance directories [2]. - The Hong Kong Medical ETF (513700) is recommended for investors looking to capitalize on the long-term growth of the Hong Kong pharmaceutical sector, as it effectively tracks the performance of the industry [2]. Group 3 - As of May 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Index accounted for 60.77% of the index, including companies like BeiGene, WuXi Biologics, and Innovent Biologics [3].

Group 1 - The core point of the article highlights the performance of the China Europe Medical Innovation Stock C fund, which has shown a net value of 1.2838 yuan, reflecting a growth of 1.42% [1] - The fund's one-month return is 8.30%, ranking 36 out of 1025 in its category, while its six-month return is 22.03%, ranking 30 out of 987 [1] - Year-to-date, the fund has achieved a return of 27.56%, ranking 31 out of 999 in its category [1] Group 2 - The top ten holdings of the China Europe Medical Innovation Stock C fund account for a total of 75.62%, with the largest positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan, managed by fund manager Ge Lan [1] Group 3 - Ge Lan, the fund manager, holds a PhD in Biomedical Engineering from Northwestern University and has extensive experience in the investment management field, having worked with various funds since joining China Europe Fund Management in October 2014 [2]

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry, specifically recommending an "Accumulate" rating for both the pharmaceutical manufacturing and pharmaceutical services sectors [1][2]. Core Insights - Continuous attention is suggested on innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug industry is experiencing a high demand for assets, with multinational corporations showing greater interest than concerns over geopolitical risks [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Monthly Portfolio Performance - The report highlights a monthly portfolio for June 2025, including companies such as Jiangsu Heng Rui Medicine, Huadong Medicine, and Sichuan Kelun Pharmaceutical, among others [5][36]. - In May 2025, the portfolio achieved an average increase of 7.7%, outperforming the overall pharmaceutical index, which rose by 4.5% [11][37]. Market Performance - In May 2025, the pharmaceutical sector ranked first in performance, with notable sub-sectors like chemical raw materials (+10.5%) and chemical preparations (+9.6%) showing strong growth [20][37]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. International Market Comparison - The Hong Kong pharmaceutical sector outperformed the market with a rise of 7.8%, while the U.S. pharmaceutical sector underperformed, declining by 5.7% [38]. - The report identifies top-performing stocks in both markets, with significant gains in the Hong Kong sector and notable declines in the U.S. sector [38].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].